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Abstract
Background:  Growth inhibition by RPR-130401, a non-peptidomimetic farnesyltransferase
inhibitor, was investigated without or with combined exposure to ionizing radiation in three human
tumor cell lines (HCT-116, MiAPaCa-2 and A-549) bearing a point mutation in the K-Ras gene.
Results: RPR-130401 inhibited cell growth with an IC50 of 50 nM (HCT-116), 120 nM (MiAPaCa-
2) and 710 nM (A-549), with a poor incidence of apoptosis. The drug brought about G1 and S phase
depletion together with arrest of cells in G2 phase and induced a significant accumulation of
hyperploid cells showing active S phase DNA synthesis, with HCT-116 and A-549 cells being the
most and least responsive, respectively. The drug also produced dramatic changes of the nuclear
lamin B pattern, without lamin B cleavage and perturbation of the actin cytoskeleton. On the other
hand, RPR-130401 elicited strictly additive interaction in combined treatment with ionizing
radiation with regard to cell kill, altered cell cycle progression and induced hyperploidy.
Conclusions: The data suggest that disruption of orderly progression through mitosis and
cytokinesis, is a major outcome of drug action and that this effect proceeds from inhibition of lamin
B farnesylation. It is anticipated from the strict additivity of RPR-130401 and radiation that neither
induced radiation resistance nor acute or late complications of radiotherapy, should occur in
combined treatment with RPR-130401.
Background
For over ten years chemo-radiotherapeutic combinations
have evolved as prevalent modalities in the cure of solid
tumors. The rationale for these treatments relies mostly
on the drugs' ability to sterilize disseminated metastases
(spatial cooperation) and on radiation-drug interaction
for improved local control of the primary tumor. Supraad-
ditive interaction, often resulting from impaired repair of
radiation-induced sublethal damage, may lead to limiting
toxicities. In contrast, pure additivity of the treatments
may conceivably be turned to advantage because the dose-
dependent response of cells to radiation includes a quad-
ratic term. This is of concern, for example, to farnesyl
transferase inhibitors (FTIs) of which six have already
been tested in phase I clinical trials [1,2] with most atten-
tion being paid to the non-peptidomimetic R115777 [3–
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5]. As one may expect a cytostatic rather than a cytotoxic
effect from FTIs, assays of combined modality treatment
with cytotoxic agents applied in close temporal proximity
should be performed. This prompted us to investigate the
cells' response to RPR-130401 (Scheme 1), a non-peptid-
omimetic FTI issued from chemical optimization from se-
ries selected by random screening at Rhône-Poulenc-Rorer
Co. [6], both alone or in concomitant association with
ionizing radiation.
A comprehensive approach to these problems requires an
insight into the molecular targets of drug action. Together
with mutation or deletion of the p53 tumor suppressor
gene, mutations in one of the four Ras genes (H-, N-, KA-
and KB-Ras) represent the most frequent genetic altera-
tions in human cancers [7] with predominance in pancre-
atic (90%), colorectal (50%) and lung (20%) tumors (for
a review on ras mutations in relation to oncogenic trans-
formation see [2]). Activation of Ras proteins requires pre-
nylation of the CAAX sequence at their C-terminus, to
ultimately permit their association with other proteins [8]
or with the inner face of the plasma membrane [9]. A key
step in this process is catalyzed by farnesyltransferase
(FTase). The K-Ras protein can alternatively be prenylated
by type I geranylgeranyltransferase (GGTase I), a closely
related enzyme [10].
FTase has been a very attractive target for antitumor drug
discovery because prenylation is required for oncogenic
Ras to transform cells [11–13]. Numerous inhibitors have
been developed, including FPP analogs, CAAX peptide
analogs, bisubstrate analogs [14,15] and more recently
GGTase I inhibitors [16]. However, it is now known that
a range of non-Ras proteins are targets for prenylation
[17–19]. In spite of this, the quest for specific FTase-target-
ing drugs that would not affect GGTase is still pertinent,
because geranylgeranylation of normal cellular proteins is
five to ten times more prevalent than farnesylation
[20,21].
RPR-130401 acts as a competitive inhibitor of the FPP
substrate with respect to the farnesylated proteins, with an
IC50 of 28 nM for the inhibition of K-Ras prenylation in
vitro[6], and has demonstrated in vivo antitumor activity in
mice bearing human carcinoma xenografts [22]. RPR-
130401 is highly selective (more than 300-fold) for FTase
with regards to GGTase, an unexpected result since GG-
Tase can accommodate and transfer both FPP and geran-
ylgeranyl pyrophosphate to CAAX-motifs in proteins [23].
Consistently, RPR-130401 efficiently inhibits Ras far-
nesylation in cells but does not block geranylgeranyl
transfer to Ras [24]. RPR-130401 is also very efficient in
inhibiting lamin B farnesylation [6]. The lack of protein
substrate specificity is of particular interest for the devel-
opment of this series of FTIs, as non-Ras farnesylated pro-
teins may participate in transformation by Ras-dependent
or -independent pathways. The discovery of prenylation-
dependent oncogenic protein tyrosine phosphatases har-
boring a CAAX-box [25] strengthens the interest for such
FTIs as RPR-130401.
For studies with RPR-130401 we chose three cell lines
bearing a K-Ras allele with a point mutation, namely, the
human colon adenocarcinoma HCT-116 with mutation at
codon 13 [26], the human pancreatic carcinoma MiA-
PaCa-2 with mutation at codon 12 [27], and the human
lung carcinoma A-549 with another mutation at codon 12
[28]. Cell growth or survival, cell cycle progression, ploi-
dy, lamin B structure in nuclear lamina, cytoskeleton
framework, and lamin B fragmentation were taken as an
endpoint in single or combined treatment with ionizing
radiation. The data show that RPR-130401 affects the in-
tegrity of the lamin B network, resulting in an aberrant on-
set of mitosis and cytokinesis and ensuing hyperploidy
without significant changes in radiation susceptibility.
Results
Growth inhibition by RPR-130401
The response of HCT-116, A-549 and MiAPaCa-2 cells to
RPR-130401 was investigated through growth inhibition
assays with exponentially growing subcultures. Cells were
exposed to the drug for up to 7-days at concentrations in
the range 2.5–7,000 nM. RPR-130401 was found to inhib-
it cell growth with an IC50 of 50 nM for HCT-116, 120 nM
for MiAPaCa-2 and 710 nM for A-549 cells. The effect cor-
related with a pronounced lengthening of the cells' dou-
bling time (Figure 2).
Scheme 1
Chemical Structure of RPR-130401BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/2
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Figure 2
Growth inhibition by RPR-130401 in asynchronously growing HCT-116, A-549 and MiAPaCa-2 cells. Mid-log phase cells were
seeded (2 ×  105 cells in 25 cm2 flasks) and incubated for 24-h prior to introduction of RPR-130401. The drug was present for
up to the time of trypsinization and cell scoring. RPR-130401 induced a pronounced lengthening of the cell doubling time,
namely, for HCT-116 cells, 23-h (50 nM drug = 1 ×  IC50) or 30-h (500 nM drug) vs. 18-h in drug-free controls; for A-549 cells,
30-h (0.71 µM drug = 1 ×  IC50) or 35-h (7.1 µM drug) vs. 22-h in drug-free controls; for MiAPaCa- 2 cells, 35-h (0.12 µM drug
= 1 ×  IC50) or 40-h (1.2 µM drug) vs. 23-h in drug-free controls.BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/2
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Altered cell cycle progression by RPR-130401 and radia-
tion
To investigate cell cycle redistribution by RPR-130401,
HCT-116, MiAPaCa-2 and A-549 cells were exposed for 5-
days to 1 ×  IC50 or 10 ×  IC50 FTI (relative to the cell line
of interest) and submitted or not to γ -rays 24-h before har-
vest. BrdUrd was incorporated at the end of treatment for
S-phase cell labeling. The three cell lines were not equally
responsive to drug (Figure 3). RPR-130401 induced accu-
mulation of HCT-116 cells in G2-M phase, with a concen-
tration-dependent increase in the ploidy number and a
decline in the normodiploid G1- and S-phase content.
These observations correlate those made by other authors
using Ras-mutated human pancreatic cells and L-744,832
[29] or human lung cancer cells and FTI-2153 [30]. MiA-
PaCa-2 cells showed a similar response at low (1 ×  IC50)
drug concentration. However, with this cell line both the
G1 phase depletion and the increase in the ploidy
number, were substantially less pronounced at high (10 ×
IC50) than at low (1 ×  IC50) drug concentration. Finally,
with the exception of the pre-mitotic arrest, the effect of
RPR-130401 on cell cycle progression and ploidy change
was comparatively minor in A-549 cells. Irradiation pro-
moted drug-induced effects. Incidentally, flow cytometric
analysis did not provide evidence of a significant amount
of the sub-G1 DNA fragments expected from apoptosis.
Radiation survival in the presence of RPR-130401
Two methods were used to determine whether RPR-
130401 resulted or not in an altered radiation survival.
For lengths of drug exposure in excess of 12-h (1- to 5-
days), cells were trypsinized and plated following treat-
ment to preclude artifacts due to cell multiplicity. Short
contact with drug (1-, 2-, 3- or 12-h) was performed in the
most sensitive cell line only, i.e., in HCT-116 cells. In that
case, cells were plated prior to treatment and the data cor-
rected for changes in cell multiplicity (see Materials and
Methods) where necessary. A total of 78 survival curves
were generated and fitted to eq. (2) (see Materials and
Methods) for data analysis. Irrespective of the method
used, exposure of cells to RPR-130401 did not produce
any significant modification of radiation sensitivity rela-
tive to controls, even with the largest drug concentration
and the longest length of drug exposure (Figure 4).
Effects of RPR-130401 on lamin B distribution
Altered distribution of lamin B following exposure to the
FTI was investigated in HCT-116, A-549 and MiaPaCa-2
cells. Cells were exposed for 5-days to 1 ×  IC50 or 10 ×  IC50
RPR-103401, submitted or not to γ -rays 24-h before har-
vest and lamin B was subsequently probed by immun-
ofluorescence. Typical results are shown in Figure 5.
Control cells (Figure 5A,5D & 5G) showed a nuclear dis-
tribution of lamin B with localization to the nuclear lam-
Figure 3
Effect of RPR-130401 on cell cycle progression. Cells were
grown for a total of 5-days without or with 1 ×  IC50 or 10 ×
IC50 RPR-130401. At day 4, part of samples was irradiated to
the dose indicated and allowed to rest in the incubator for an
additional 24-h prior to harvest. The DNA content was
determined from flow cytometric analysis of propidium
iodide staining and BrdUrd incorporation. 104 nuclei were
analysed for each sample. 2C, 4C and 8C, diploid, tetraploid
and octoploid cells. Sq, quiescent (arrested in synthesis) S-
phase cells.BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/2
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ina as indicated by a ring-like staining at the nuclear
periphery. During mitosis the lamin was either cytoplas-
mic (Figure 5D) or poorly detectable (Figure 5G,5H). The
pattern of lamin B distribution was markedly altered fol-
lowing incubation with RPR-130401, depending on the
cell line. For HCT-116 (Figure 5B,5C) and A-549 cells
(Figure 5E,5F), the lamin B staining was still nuclear with
the characteristic ring-like structure but, in addition to gi-
ant nuclei typical of treated HCT-116 cells (Figure 5C),
cell doublets with no proper separation of the daugther
nuclei after telophase were observed (Figure 5F). MiA-
PaCa-2 cells showed a different pattern in response to
RPR-130401 (Figure 5H,5H’). With these cells, lamin B
was not strictly confined in the nucleus as indicated by cy-
toplasmic patches (Figure 5H). Examination of DAPI-
stained nuclei confirmed the absence of DNA in these
patches (Figure 5H’). Lamin B figures were not apprecia-
bly modified by exposure to ionizing radiation; however,
radiation induced the formation of micronuclei in rela-
tion to mitotic cell death (data not shown).
Effects of RPR-130401 on actin and tubulin networks in 
HCT-116 cells
Some FTIs reportedly affect the actin cytoskeleton via the
Rho (a Ras-related GTP-binding protein) pathway [31]
and Rho-B, an endosomal Rho protein involved in recep-
Figure 4
Typical radiation survival curves for asynchronous growing cells without (•) or with exposure to 1 ×  IC50 () or 10 ×  IC50 ()
RPR-130401. Cells were plated, exposed to the drug for 3-days and irradiated. Each flask was trypsinized immediately after
irradiation and 800 to 1,000 cells were replated in drug-free medium for colony formation assays. To account for the loss of
plating efficiency du to drug exposure, survival values were normalized relative to the surviving fraction for drug alone. The
curves were drawn for best fit to a linear quadratic equation (eq. (2), see Materials and Method) taking all data points into con-
sideration. Found: α  = 0.518 ± 0.036 Gy-1, β  = 0.044 ± 0.016 Gy-2 for HCT-116 cells; α  = 0.193 ± 0.036 Gy-1, β  = 0.065 ±
0.014 Gy-2 for A-549 cells; α  = 0.189 ± 0.058 Gy-1, β  = 0.086 ± 0.026 Gy-2 for MiAPaCa-2 cells. Each data point came from an
average over three flasks or more. Bars, SD. The figure at bottom right shows the surviving fraction at 2 Gy (SF2) of HCT-116
cells in the presence of RPR-130401. The conditions were the same as above. Data were corrected for the expression of
potentially lethal damage [82].BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/2
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tor trafficking, has recently been suggested as an impor-
tant mediator of the antineoplastic potential of FTIs
[19,32]. We therefore sought to investigate the effects of
50 nM or 500 nM RPR-130401 on the distribution of actin
and tubulin networks in HCT-116-cells exposed to RPR-
130401 and/or radiation. Pictures obtained using rhod-
amine-phalloidin and immunofluorescent labeling of iso-
thiocyanate-conjugated tubulin in control and treated
cells, are shown in Figure 6.
L-739,749, another FTI, was earlier shown to induce rapid
morphological reversion of rat fibroblasts (Rat1-ras)
transformed with H-ras [33]. Such phenotypic reversion
was not observed using RPR-130401 in HCT-116 cells.
Normal membrane ruffles, circumferential actin bundles
and focal adhesions as seen in control HCT-116 cells (Fig-
ure 6A), were still present in cells incubated for as long as
5-days in the presence of RPR-130401 (Figure 6B). The
size of the nuclei and the number of giant cells grew in
parallel in the presence of the drug, up to threefold rela-
tive to controls. The stress fibers and the tubulin network
were normal in these cells (Figure 6B & 6D). Examination
of bisbenzimide-stained nuclei showed the absence of ap-
optotic bodies (Figure 6A’,6B’), and no vesicles were
formed in the cytoplasm of treated cells.
Figure 5
Immunofluorescent detection of lamin B in control (A, D, G) and treated (B, C, E, F, H, H') HCT-116 (B, C), A-549 (E, F) and
MiAPaCa-2 cells (H, H'). Cells were grown on coverslips for 5-days without or with 1 ×  IC50 (B, E, H, H') or 10 ×  IC50 (C, F)
RPR-130401. Cells were then fixed and incubated with an anti-lamin B monoclonal antibody, then with an Alexa®-conjugated
secondary antibody. To visualize nuclei, the cells were counter-stained with DAPI (H'). Cells were viewed on a Zeiss micro-
scope and photographed with Ilford HP-5 film. m, mitosis; p, cytoplasmic patches. The bar (B) represents 20 µm.BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/2
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RPR-130401-induced modification of the HCT-116 karyo-
type
Activation of Ha-ras gene expression in mouse NIH3T3
cells is known to result in genomic instability, identified
from chromosome aberrations including acentric frag-
ments, multicentric and double-minute chromosomes
[34,35]. We therefore investigated the effects of 50 nM or
500 nM RPR-130401 on the ploidy and chromosome in-
tegrity in HCT-116-cells exposed to RPR-130401 and/or
radiation. Figure 7 shows the distribution of the chromo-
some score within individual metaphases of colcemid-
treated cells after 1-day of contact with RPR-130401. Con-
trol cells showed a near-diploid karyotype with a modal
number of chromosomes of 45. Excess ploidy increased
with the drug concentration, the radiation dose and the
length of drug exposure. The mitotic index decreased dur-
ing treatment (data not shown), thus confirming that the
accumulation of HCT-116 cells was in the G2 phase.
However, no chromosome aberration was seen at this
stage using FISH analysis with all human centromeres
probes. All chromosomes in the metaphases examined
displayed one unique centromere, even in metaphases
containing up to 200 chromosomes (data not shown).
Western blot analysis of lamin B in treated cells
Flow cytometry (Figure 3) and DAPI fluorescence of nu-
clei (Figure 5), did not provide evidence of a significant
level of apoptosis in cells exposed to RPR-130401. In
some instances, however, the pictures obtained from im-
munofluorescence analysis of the lamin B status in cells ex-
posed for 5-days to RPR-130401, suggested breakdown of
nuclear lamina, and it has been shown recently that inhi-
bition of protein prenylation may cause apoptotic cell
death in pancreatic cells [36]. As lamin B cleavage into 46
kDa fragments is a hallmark of apoptosis [37], we per-
formed a Western blot determination of lamin B in extracts
from HCT-116, A-549 and MiAPaCa-2 cells exposed for 5-
days to 10 ×  IC50 RPR-130401. The results (Figure 8) un-
ambiguously show complete absence of lamin B cleavage.
Discussion
The main effects of RPR-130401 against the three K-Ras
mutated cell lines used in this study were (i) a pro-
nounced cytostatic effect, with an IC50 in the range 50–
710 nM; (ii) accumulation of cells in G2 phase, with G1
and S phase depletion; (iii) induction of a large amount
of hyperploid cells (HCT-116 and MiAPaCa-2) showing
active S-phase DNA synthesis, together with some giant
cells; (iv) profound alteration of the lamin B pattern, with-
out cleavage of the protein; (v) no alteration of the micro-
Figure 6
Immunofluorescent visualization of cytoskeleton components in control (A, A', C) and treated (B, B', D) HCT-116 cells. Cells
were grown on coverslips for 5-days without or with 500 nM RPR-130401. The cells were subsequently given 3.5 Gy γ -rays
and allowed to rest in the incubator for 24-h. Cells were then fixed and incubated with TRITC-labeled phalloidin (A, B), or with
an anti-α  tubulin FTIC-conjugated antibody (C, D). Nuclei were counter-stained with bisbenzimide (A', B'). Cells were viewed
as in Figure 5. The bar (C) represents 20 µm.BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/2
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tubule and actin networks, even after prolonged
incubation with a high drug concentration in the most
sensitive cell line (500 nM, HCT-116 cells); (vi) strictly ad-
ditive interaction with ionizing radiation with regard to
cell kill, cell cycle redistribution and induction of hyper-
ploidy.
Two alternative pathways should be taken into considera-
tion in order to explain these observations, namely, inhi-
bition of the farnesylation of p21Ras or related proteins
from the Ras superfamily, or inhibition of the farnesyla-
tion of other proteins resulting in disruption of the mitot-
ic apparatus or cytokinesis traverse. These hypotheses are
discussed below.
p21Ras activation in normal and tumor cells is mandatory
to the transition from cell quiescence to proliferation.
However, it is generally agreed that inhibition of p21Ras
farnesylation does not suppress mitogenic functions in
Ras-transformed cells [38]. Moreover, it has recently been
shown that growth inhibition by FTIs does not necessarily
proceed from inhibition of p21Ras prenylation, and that
various Ras-unrelated proteins may be important targets
for FTI treatment [2,19,29,39,40]. Even though it results
in an altered subcellular distribution of p21Ras[6], RPR-
130401 is not able to block p21Ras geranylgeranylation
[24] in such a way that inhibition of p21Ras farnesylation
is not likely to account for the main effects of the drug. On
the other hand, the peptidomimetic FTI L-739,749 has
been reported to prevent Ras-induced transformation
through inhibition of Rho-B prenylation [31] with a block
in cell proliferation, increased apoptosis [41] and major
changes in stress fiber formation, cell shape and mobility.
None of these characteristic changes in cell morphology
and architecture was observed upon prolonged exposure
to RPR-130401 (Figure 6), which seems to rule out any
member of the Rho family as a target for RPR-130401.
Considering the efficient pre-mitotic block and hyperploi-
dy induced by RPR-130401, as also found with other FTIs
[16,29,30,42], it is tempting to postulate that the target of
the drug is a protein involved at some stage in mitosis
and/or cytokinesis, and whose farnesylation is required
for proper activation. Indeed, protein isoprenylation is
important at the G2/M transition in Schizosaccharomyces
pombe[43] and nuclear lamins are major targets for FTase
[18,44]. Lamin B farnesylation, which is a very sensitive
target for RPR-130401 in vitro[6], appears to deserve con-
Figure 7
Effect of RPR-130401 exposure on the chromosome number distribution in individual metaphases. HCT-116 cells were grown
for 4-days without (A, B) or with 50 nM (C, D) or 500 nM (E, F) RPR-130401. Cells were then given 3.5 Gy γ -rays (B, D, F) and
returned to the incubator for 24-h prior to fixation and scoring. Each panel represents the counts from at least 50 metaphases.BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/2
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sideration as a candidate to this role. As a matter of fact,
among the three major type A-C lamins, lamin A and lam-
in B are initially translated with a CAAX motif. This motif
is cleaved upon post-translational maturation of lamin A
but persists in lamin B, unless the C-terminal aminoacid
residue is mutated [23]. Studies with mutant lamin delet-
ed of the CAAX sequence have shown that the CAAX motif
is essential to anchoring lamin B to the nuclear envelope
[45,46]; moreover, farnesylation is required for the inte-
gration of newly synthesized lamins into the pre-existing
nuclear lamina during interphase, and GGTase is unable
to substitute for FTase at this stage [47].
These data altogether suggest that inhibition of lamin B
farnesylation could be an important target of RPR-
130401, resulting in an aberrant onset of mitosis and cy-
tokinesis and ensuing hyperploid cell generation. Strong
support to this scheme is given by immunofluorescence
experiments showing that the intranuclear distribution of
lamin B is profoundly altered in cells exposed to RPR-
130401 (Figure 5). This occurred without lamin B break-
down (Figure 8), consistent with lack of a significant level
of apoptosis in the three cell lines used. Interestingly SCH-
66336, another FTI, reportedly allows accumulation of
unfarnesylated prelamin A in patients under phase I inves-
tigation [1] and in several cell lines in culture as well [48].
It has also been shown that SCH-66336 induces diruption
of microtubule binding to the centromeric proteins
CENP-E and CENP-F [17], thus evoking again faulty mito-
sis as an important outcome of FTI exposure.
Conclusions
Oncogenic Ras expression has been reported to have dif-
ferent outcomes in rodent and human cells with regard to
radiation susceptibility. Studies in mouse [49–52] or rat
cells [51,53–59] relied on transfection with N-Ras[49,50],
H-Ras[51,53–58] or co-transfection with H-Ras and
myc[53–55], [58–60]. Except in one study [51], the au-
thors have conclusively shown that transformation of ro-
dent cells with the Ras oncogenes results in enhanced
radiation resistance. Co-transfection with H-Ras and myc
was found to act synergistically with regard to induction of
the radioresistant phenotype [53,54,58–60], possibly in
relation to inhibition of myc-dependent apoptosis [58,61].
With two exceptions in support of increased radioresist-
ance [62,63], early studies on human cells did not show
any clear-cut relationship between radiation sensitivity
and expression of oncogenic Ras[64–67]. In addition, a
study involving a cohort of patients with stage II and III
carcinoma of the uterine cervix, demonstrated the absence
of a significant correlation between rearrangements or
structure of the Ha-ras-1 and/or c-myc genes and tumor re-
sponse to radiotherapy [68]. However, the contribution of
N- or K-Ras activation to intrinsic radioresistance in hu-
man cells has recently been adressed directly, i.e., without
the perturbations introduced by cell transformation [69].
The mechanisms involved in Ras-related radioresistance
are still open to question, but it might reasonably be pro-
posed that it proceeds from constitutive activation of
pathways dowstream from Ras in signal transduction,
such as raf-1 [70] or phosphatidylinositol 3-kinase [71].
Whether and how FTase inhibition may affect the re-
sponse of cells to ionizing radiation has also been a long-
standing problem. The outcome appears to depend very
much on the cell line and the specificity of the FTI used.
The FTase inhibitor FTI-277 reportedly acted as a radio-
sensitizer in H-Ras-transformed rat embryo fibroblasts
[72] and in human tumor cells harboring H-Ras mutation
[73]. On the other hand, the radiation susceptibility of
human tumor cells expressing the wild-type form of Ras
Figure 8
Western blot analysis of lamin B in extracts from control and
treated cells. Cells were incubated for 5-days in 75 cm2 flasks
with 500 nM (HCT-116), 7.1 µM (A-549) or 1.2 µM (MiA-
PaCa-2) RPR-130401. A blank was also prepared for each cell
line. The number of cells at the time of cell lysis, was in the
range 107. At the end of treatment, the flasks were rinsed
twice with ice-cold PBS and cells lysed in PHEM buffer as
described under Materials and Methods. An aliquot of each
extract (20 µg total protein) was loaded in the wells of a
7.5% polyacrylamide gel and electrophoresis was performed
under usual conditions with molecular weight standards, fol-
lowed by transfer to a nitrocellulose membrane. The mem-
brane was incubated with a mouse monoclonal antibody
directed against human lamin B and revealed through chemi-
luminescence detection (see Materials and Methods).BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/2
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was not altered by FTIs [73]. However, enhanced radia-
tion response by FTI-277 has been described in human
cells expressing wild-type Ras together with the 24-kDa
isoform (FGF2) of basic fibroblast growth factor, a factor
involved in acquired radioresistance [74]. This was taken
as an indication that farnesylated proteins other than Ras
might be involved in the modulation of radiation re-
sponse by FTI-277 [74]. Weak radiosensitization only was
obtained with FTI-277 in K-Ras mutants, unless FTI-277
was combined with GGTI-298 to hinder geranylgeranyl
transfer to K-Ras [73]. Last but not least FTI-induced radi-
osensitization, when it occurs, seems to be independent
on the growth inhibitory effect of the FTI [73].
We show here that RPR-130401 does not significantly al-
ter the radiation susceptibility of human cells bearing K-
Ras mutation. This occurs in spite of significant hyper-
ploidization, accumulation of cells in G2 and depletion of
S phase. Finally, impaired repair of radiation damage by
RPR-130401, appears to be very unlikely to occur. This
seems valuable in the prospect of combining RPR-130401
as an adjuvant to conventional radiotherapy, as it should
provide strictly additive interaction without the local and
systemic adverse effects inherent in treatments with radia-
tion sensitizers [75]. In this respect it is very exciting to
note that two farnesyltransferase inhibitors, FTI-276 and
L-744,832, have recently proven to act synergistically with
ionizing radiation in vivo for growth inhibition of
xenotransplanted  H-Ras-mutated human tumor cells,
without increase in acute or long-term radiation-induced
damage to healthy tissues [76].
Materials and methods
Reagents
RPR-130401 was synthesized as described [77] and stored
at -20°C as a 20 mM stock solution in DMSO. Prior to use,
the solution was diluted first into medium containing
20% DMSO, then to the final concentration in culture
medium. DMSO was kept below 0.1% so as not to alter
cell growth or radiation response.
Colcemid and all products from cell culture were from In-
vitrogen (Cergy-Pontoise, France). BrdUrd, propidium io-
dide, bisbenzimide, DAPI, Giemsa stain, TRITC-
phalloidin and mouse anti-α -tubulin monoclonal anti-
body (clone DM1A) came from Sigma-Aldrich (Saint-
Quentin-Fallavier, France). Mouse monoclonal antibod-
ies directed against lamin B was from Oncogene Research
Products (San Diego, California). FITC-conjugated sheep
anti-mouse IgG was from Sanofi-Synthélabo (Paris,
France). Alexa® 488 goat anti-mouse IgG conjugate was
from Molecular Probes (Eugene, Oregon). Rat mono-
clonal antibody directed against BrdUrd was purchased
from Harlan Sera-Lab (Loughborough, United Kingdom),
and fluorescein isothiocyanate-conjugated goat anti-rat
IgG (heavy chain specific) was from Southern Biotechnol-
ogy Associates (Birmingham, Alabama). Human centro-
mere probes for FISH was obtained from QBiogene
(Illkirch, France). Solvents and chemicals were of the
highest purity available and came from Merck Eurolab
(Paris, France).
Cell culture
HCT-116 human colon carcinoma (ATCC CCL-247), MiA-
PaCa-2 human pancreatic carcinoma (ATCC CRL-1420)
and A-549 human lung carcinoma cells (ATCC CCL-185)
were grown as monolayers in DMEM (HCT-116, MiAPaCa-
2) or RPMI-1640 (A-549 cells) containing sodium pyruvate
and Glutamax I, and supplemented with 10% foetal calf se-
rum, 100 IU/ml penicillin, and 0.1 mg/ml streptomycin.
Cells were routinely subcultured after trypsinization at a
density of 6,000 cells/cm2 in culture flasks every 5-days and
incubated at 37°C in a humidified atmosphere of 7% CO2
in air. Less than 9–10 passages of the same primary subcul-
ture were allowed. Prior to seeding, cells were rinsed twice
with HBSS, harvested by trypsin-EDTA treatment and
counted in an hemocytometer.
Survival assays
Radiation survival with or without combined drug expo-
sure was determined by clonogenic assays. For determina-
tion of the response to radiation alone, cells from
exponentially growing subcultures were seeded in 25 cm2
flasks at the suitable density, incubated for 3-h to allow
cells to adhere and spread, and irradiated in culture medi-
um at room temperature in an IBL-637 (137Cs) irradiator
(CIS-Biointernational, Saclay, France) at a dose-rate of
0.92 Gy/min. All experiments were performed in triplicate
or more.
Two protocols were used in single or combined treatment
assays. For short lengths of drug exposure (≤  12-h), 1,000
cells were plated in triplicate in 25 cm2 flasks and incubat-
ed for 3-h. Cells were then exposed to drug for 1-, 2-, 3-,
4- or 12-h, irradiated and returned to the incubator for 1-
h in the presence of RPR-130401, followed by two washes
with HBSS and feeding with drug-free medium. Colonies
were allowed to grow for 8–11 days, then fixed with meth-
anol, stained with Giemsa and scored. Small colonies (<
30–50 cells) were disregarded. Results were corrected for
cell multiplicity (see below).
Where the length of drug exposure was in excess of 12-h,
cells were plated after treatments to avoid biases due to
the formation of microcolonies. Typically, cells were plat-
ed in 25 cm2 flasks and exposed to drug for 1-, 2-, 3-, 4- or
5-days, and irradiated. Seeding was adjusted so as to ob-
tain an equal number of cells at the time of irradiation,
taking into consideration the cytostatic effect of the FTI
and the length of drug exposure. Each flask wasBMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/2
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trypsinized immediately after irradiation, the cells were
counted and 1,000 cells per flask were replated in drug-
free medium for colony formation assays.
Flow cytometry and cytogenetic analysis
Cell cycle progression was monitored by dual parameter
flow cytometry using a FACStar PLUS cytofluorometer
(Becton Dickinson, Le Pont de Claix, France). Cells were
grown for 3- to 6-days with or without RPR-130401. At
that time, flasks were irradiated to 3.5 Gy (HCT-116), 5
Gy (A-549) or 5.5 Gy (MiAPaCa-2) and allowed to rest in
the incubator for 24-h prior to fixation. 15-min before
harvesting, cells were incubated with BrdUrd (10 µM) for
pulse-labeling of S-phase cells, then collected, washed
once with cold PBS and fixed in 70% ice-cold ethanol.
Treatment of fixed cells for cytofluorimetric analysis, data
acquisition and processing were done according to De-
marcq et al.[78]. Cell cycle analysis was performed with
ProCyt software (CEA-INSERM, Grenoble, France).
Alternatively, HCT-116 treated cells were incubated with
0.2 µg/ml colcemid for 1-h, washed twice with HBSS and
allowed to swell for 30-min in 75 mM KCl hypotonic so-
lution. Cells were then fixed in 3:1 v/v methanol:acid ace-
tic in ice and washed threefold in the same solvent. Fixed
cells were dropped onto glass slides to spread chromo-
somes, and air dried. Slides were stained with Giemsa be-
fore scoring.
Immunofluorescence
For immunofluorescence characterization, cells were
grown on 20 ×  20 mm coverslips in medium containing
10% foetal calf serum for 3- to 6-days with or without
RPR-130401. At that time, the coverslips were irradiated
to 3.5 Gy (HCT-116), 5 Gy (A-549) or 5.5 Gy (MiAPaCa-
2) and allowed to rest in the incubator for 24-h prior to
fixation.
To visualize polymerized actin and tubulin, cells were
processed according to Mies et al.[79]. Briefly, cells were
fixed in 0.25% glutaraldehyde, 0.5% Triton X-100 for 1-
min, followed by 10-min in freshly prepared 4% formal-
dehyde and extensive washing. The coverslips were then
incubated (30-min, 37°C) with 0.2 µg/ml TRITC-labeled
phalloidin, or with a 1:200 working dilution of mono-
clonal anti-α  tubulin antibody followed by a 30-min in-
cubation with a 1:1,000 dilution of FITC-conjugated
sheep anti-mouse IgG at 37°C.
To visualize lamin, cells were fixed in acetone/methanol
(1:1, v/v) for 20-min at -20°C, allowed to air dry, then
washed 3 times with PBS and treated with 0.5% Triton X-
100 for 5-min at 4°C to permeabilize cells. The coverslips
were incubated (30-min, 37°C) with 5 µg/ml of mono-
clonal anti-lamin B antibody followed by a 30-min incu-
bation with 1:500 Alexa® 488 goat anti-mouse IgG
conjugate.
To visualize nuclei, the cells were counter-stained with
bisbenzimide (0.2 µg/ml) or DAPI (0.12 µg/ml). Cells
were viewed on a Zeiss microscope and photographed
with Ilford HP-5 film.
Western blots
For determination of lamin B cleavage, HCT-116, A-549
and MiAPaCa-2 cells were exposed for 5-days at 10 ×  IC50
each of RPR-130401. At the end of treatment, cells were
harvested in PBS with 2 mM EDTA and lysed for 20-min
on ice with gentle agitation in PHEM buffer (80 mM
PIPES, 80 mM HEPES, 10 mM EDTA, 5 mM MgCl2, 1%
Triton X-100, pH 7.4) supplemented with 1 mM PMSF, 10
µg/ml aprotinin and 1 µg/ml each of leupeptin and pep-
statin. The insoluble fraction, containing lamin B, was re-
covered by centrifugation, solubilized in Laemmli buffer
(3% lauryl sulfate, 10% glycerol, 5% 2-mercaptoethanol,
62.5 mM Tris-HCl, pH 6.8) and titrated.
An aliquot (20 µg total protein) of each extract was loaded
onto 7.5% polyacrylamide gel, electrophoresed, and blot-
ted onto nitrocellulose (Schleicher & Schuell, Dassel, Ger-
many). The membrane was saturated with bovine serum
albumine and incubated with a mouse monoclonal anti-
body directed against lamin B. Protein detection was car-
ried out using a peroxidase-conjugated goat anti-mouse
secondary antibody and an ECL kit (Amersham Pharma-
cia Biotech, Orsay, France). Quantification was performed
by densitometry with the aid of QuantityOne® software
(Bio-Rad, Hercules, California).
Curve fittings and correction for cellular multiplicity
Care was taken to avoid contamination of seed cell sus-
pensions by clusters, as their presence introduces large,
systematic errors in viability measurements with clono-
genic assays [80]. For this reason, the cellular multiplicity,
i.e., the number of cells per potential colony-forming unit
was carefully checked by microscope observation at the
time of irradiation throughout the whole study. When the
average multiplicity was less than 1.1 (for 1- and 2-h drug
exposure), no correction was applied. Corrections were
necessary for longer lengths of drug exposure (≥  3-h), be-
cause viable colony-forming units contained a substantial
amount of doublets and quadruplets at these times. In
that case, the equation:
(where Sexp is the experimental cell survival determined
from bulk colony scoring and an the fraction of colony-
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forming units with n viable cells) was used in order to cal-
culate the single-cell surviving fraction (SCSF).
Radiation survival curves with or without co-treatment
with RPR-130401 were drawn for best fit to a linear-quad-
ratic equation, as usual [81]:
where S0 is the clonogenic efficiency, S the residual surviv-
al, D the radiation dose, and α  and β  numerical parame-
ters characterizing the radiosensitivity of the cell line.
Equation (1) was solved with the aid of a home-made
program. Least-squares regressions were performed on a
Macintosh microcomputer using Kaleidagraph software
(Synergy Software, Reading, Pennsylvania).
List of abbreviations
FTase, farnesyltransferase;
FPP, farnesyl pyrophosphate;
FTI, farnesyltransferase inhibitor; 
GGTase, geranylgeranyl transferase; HBSS, Hank's bal-
anced salt solution;
BrdUrd, 5-Bromo-2'-deoxyuridine;
PMSF, phenylmethylsulfonyl fluoride;
FISH, Fluorescence In Situ Hybridation; IC50, amount of
drug that reduces the growth of treated cells to 50% of that
of controls.
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